MALLINCKRODT PLC : Mallinckrodt Pharmaceuticals Announces Positive …
4-traders (press release)
Mallinckrodt (NYSE: MNK) today reported data that investigational drug MNK-795 achieved the primary endpoint in a Phase 3 efficacy trial in the treatment of acute pain following a bunionectomy.
In the study, MNK-795 showed statistically significant …http://www.4-traders.com/MALLINCKRODT-PLC-13450292/news/Mallinckrodt-PLC–Mallinckrodt-Pharmaceuticals-Announces-Positive-Phase-3-Efficacy-Results-for-MNK-17242621/
